Cargando…
Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone
IMPORTANCE: Prospective evidence suggests abiraterone is associated with superior progression-free survival for African American men compared with non-Hispanic White men with metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE: To investigate differences in outcomes with first-line ab...
Autores principales: | Marar, Mallika, Long, Qi, Mamtani, Ronac, Narayan, Vivek, Vapiwala, Neha, Parikh, Ravi B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733836/ https://www.ncbi.nlm.nih.gov/pubmed/34985518 http://dx.doi.org/10.1001/jamanetworkopen.2021.42093 |
Ejemplares similares
-
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
por: Parikh, Mamta, et al.
Publicado: (2021) -
Features of hepatocellular carcinoma in Hispanics differ from African Americans and non-Hispanic Whites
por: Venepalli, Neeta K, et al.
Publicado: (2017) -
Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014) -
Elevated depressive symptoms and incident stroke in Hispanic, African-American, and White older Americans
por: Glymour, M. Maria, et al.
Publicado: (2011) -
Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
por: Cheng, Heather H., et al.
Publicado: (2015)